BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36800845)

  • 21. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches.
    Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
    JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea.
    Kim Y; Park I; Kim B; Choi YJ; Oh SC; Lee KA
    Ann Lab Med; 2023 Jan; 43(1):64-72. PubMed ID: 36045058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
    Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
    Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response.
    Chen J; Tang Y; Liu H; Sun G; Liu H; Zhao J; Wang Z; Zhang Y; Lou F; Cao S; Qin J; Wang H; Liao B; Zeng H
    Cancer Med; 2023 Dec; 12(24):22370-22380. PubMed ID: 37986697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    Zong H; Zhang J; Xu Z; Pan JN; Wang R; Han J; Jiang M; Ren R; Zang L; Wang H; Cao WM
    J Cancer; 2022; 13(4):1119-1129. PubMed ID: 35281878
    [No Abstract]   [Full Text] [Related]  

  • 27. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
    [No Abstract]   [Full Text] [Related]  

  • 28. Alterations in homologous recombination repair genes in prostate cancer brain metastases.
    Rodriguez-Calero A; Gallon J; Akhoundova D; Maletti S; Ferguson A; Cyrta J; Amstutz U; Garofoli A; Paradiso V; Tomlins SA; Hewer E; Genitsch V; Fleischmann A; Vassella E; Rushing EJ; Grobholz R; Fischer I; Jochum W; Cathomas G; Osunkoya AO; Bubendorf L; Moch H; Thalmann G; Ng CKY; Gillessen S; Piscuoglio S; Rubin MA
    Nat Commun; 2022 May; 13(1):2400. PubMed ID: 35504881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis.
    Andrikopoulou A; Zografos E; Apostolidou K; Kyriazoglou A; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Liontos M; Dimopoulos MA; Zagouri F
    Front Oncol; 2022; 12():1030786. PubMed ID: 36531003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
    Unlu S; Kim JW
    Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PARP inhibitors in advanced prostate cancer: when to use them?
    Díaz-Mejía N; García-Illescas D; Morales-Barrera R; Suarez C; Planas J; Maldonado X; Carles J; Mateo J
    Endocr Relat Cancer; 2021 Jul; 28(8):T79-T93. PubMed ID: 34256353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.
    Kato T; Matsubara N; Shiota M; Eto M; Osawa T; Abe T; Shinohara N; Yasumizu Y; Tanaka N; Oya M; Nishimoto K; Hayashi T; Nakayama M; Kojima T; Namikawa K; Fujisawa T; Okano S; Hida E; Nakamura Y; Bando H; Yoshino T; Nonomura N
    BMC Cancer; 2022 Dec; 22(1):1292. PubMed ID: 36494792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients.
    Tao J; Sun D; Zhou H; Zhu J; Zhang X; Hou H
    Pathol Res Pract; 2022 Oct; 238():154074. PubMed ID: 35988354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients.
    Liu Y; Jin B; Shen C; Gao X; Qi X; Ma M; Li H; Hao H; Tang Q; Yang K; Mi Y; Guan J; Feng X; He Z; Li H; Yu W
    Front Oncol; 2023; 13():1086517. PubMed ID: 37064136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Fujimoto N; Harada K; Shiota M; Tomisaki I; Minato A; Nagata Y; Kimuro R; Harada M; Fujisawa M
    Anticancer Res; 2021 Oct; 41(10):4687-4695. PubMed ID: 34593416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
    Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
    Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Application of next-generation sequencing in detection of BRCA1/2 and homologous recombination repair pathway multi-genes germline mutation and correlation analysis].
    Chen YL; Zhuo ZL; Liu C; Xie F; Yang ZY; Liu PF; Wang S; Zhao XT
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Mar; 56(3):302-311. PubMed ID: 35381651
    [No Abstract]   [Full Text] [Related]  

  • 40. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.